Letter Agreement, dated April 12, 2022, between Alpine Immune Sciences Inc. and AbbVie Global Enterprises Ltd. amending the Option and License Agreement, dated June 17, 2017, by and between Alpine Immune Sciences Inc. and AbbVie Global Enterprises Ltd. (as assignee of AbbVie Ireland Unlimited Company)
Contract Categories:
Intellectual Property
›
License Agreements
EX-10.2 3 alpn-ex102_20220630.htm EX-10.2 Document
Alpine Immune Sciences Inc.
188 E Blaine St Suite 200
Seattle, WA 98102
United States
Attention: Paul Rickey, CFO
CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED AS [***].
April 12, 2022
Alpine Immune Sciences Inc.
188 E Blaine St Suite 200
Seattle, WA 98102
United States
Attention: Paul Rickey, CFO
Re: The Option and License Agreement between Alpine Immune Sciences Inc. (“Alpine”) and AbbVie Global Enterprises Ltd. (as assignee of AbbVie Ireland Unlimited Company) (“AbbVie”), made and entered into as of June 17, 2017 (the “Agreement”)
To Whom it May Concern:
This letter serves to memorialize the agreement between AbbVie and Alpine to replace Schedule 1.157 of the Agreement with the Schedule 1.157 attached to this letter as Exhibit A.
Please countersign this letter below and return a copy to AbbVie. This letter will be effective upon execution by each of the parties. If you have any questions regarding this letter, please contact John Larson, Senior Director, Alliance Management, at [***].
Sincerely,
/s/ Arthur C. Price
AbbVie Global Enterprises Ltd.
Name: Arthur C. Price
Title: Director
Agreed:
/s/ Paul Rickey
Alpine Immune Sciences Inc.
Name: Paul Rickey
Name: Paul Rickey
Title: CFO
Exhibit A
Schedule 1.157
[***] Success Completion Criteria
[***]
